New SEC Form D filing
Ansa Biotechnologies, Inc., 2026-11-18
A new SEC Form D private-offering notice from Emeryville, CA, a $71,903,290 filer-stated offering target in Biotech. The source filing is one click away.
What this filing says
Develops enzymatic DNA synthesis technology for producing complex, clonal DNA sequences and constructs
New filing yesterdayFiled to raise $71,903,290First money in 2026-10-16Raised so far $54,403,290HQ (as filed) Emeryville, CASector Biotech web-verified against the company’s own siteStage (inferred) GrowthCall status Delayed filing
Source linked the Form D on EDGAR↗Website verified ansabio.com↗Named in the filing 10 executives & directors
This is a public SEC Form D private-offering notice, the filer's own statement to the SEC. Amounts are offering targets, not confirmed closes. Takeoff Radar pulls Form D nightly from EDGAR and links every filing to its source.
Other Form D filings from the same week
each with its own page and its own EDGAR source- Robot.com Holdings, Inc., 2026-11-18, $25M, San Francisco, CA
- Linnaeus Therapeutics, Inc., 2026-11-18, $10M, Haddonfield, NJ
- Galvanize Therapeutics, Inc., 2026-11-18, $136.2M, Redwood City, CA
- Kura Oncology, Inc., 2026-11-18, $25M, San Diego, CA
- OnRails Technologies Inc., 2026-11-17, $7M, Stanford, CA
- NewcelX Ltd., 2026-11-18, $2.9M, Kloten
The Monday digest, free
A summary of who raised money last week: the ones worth a call first, then every company that filed, by state and sector. One email, Monday mornings. No spam, unsubscribe anytime.
By subscribing you agree to our Terms and Privacy Policy.